NDC 70860-225

Bortezomib

Bortezomib

Bortezomib is a Intravenous; Subcutaneous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Athenex Pharmaceutical Division, Llc.. The primary component is Bortezomib.

Product ID70860-225_49aeb918-1016-4748-aa7a-53c51014e650
NDC70860-225
Product TypeHuman Prescription Drug
Proprietary NameBortezomib
Generic NameBortezomib
Dosage FormInjection, Powder, Lyophilized, For Solution
Route of AdministrationINTRAVENOUS; SUBCUTANEOUS
Marketing Start Date2022-05-06
Marketing CategoryANDA /
Application NumberANDA210824
Labeler NameAthenex Pharmaceutical Division, LLC.
Substance NameBORTEZOMIB
Active Ingredient Strength4 mg/1
Pharm ClassesProteasome Inhibitor [EPC], Proteasome Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 70860-225-10

1 VIAL, SINGLE-DOSE in 1 CARTON (70860-225-10) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE
Marketing Start Date2022-05-06
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "Bortezomib" or generic name "Bortezomib"

NDCBrand NameGeneric Name
0409-1703BORTEZOMIBBORTEZOMIB
0409-1704BORTEZOMIBBORTEZOMIB
10019-991BORTEZOMIBbortezomib
25021-244BORTEZOMIBBORTEZOMIB
43598-865BortezomibBortexomib
50742-484BortezomibBortezomib
51817-586Bortezomibbortezomib
55150-337BORTEZOMIBBORTEZOMIB
60505-6050BORTEZOMIBbortezomib
63323-721BortezomibBortezomib
63323-821BortezomibBortezomib
67184-0530BortezomibBortezomib
68001-540BortezomibBortezomib
70710-1411BORTEZOMIBBORTEZOMIB
70771-1708BORTEZOMIBBORTEZOMIB
70860-225Bortezomibbortezomib
63020-049VELCADEbortezomib

© 2022 FDA.report
This site is not affiliated with or endorsed by the FDA.